Arcticzymes Technologies ASA (AZT) - Total Assets
Based on the latest financial reports, Arcticzymes Technologies ASA (AZT) holds total assets worth Nkr361.41 Million NOK (≈ $38.03 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Arcticzymes Technologies ASA net assets for net asset value and shareholders' equity analysis.
Arcticzymes Technologies ASA - Total Assets Trend (2002–2025)
This chart illustrates how Arcticzymes Technologies ASA's total assets have evolved over time, based on quarterly financial data.
Arcticzymes Technologies ASA - Asset Composition Analysis
Current Asset Composition (December 2025)
Arcticzymes Technologies ASA's total assets of Nkr361.41 Million consist of 85.2% current assets and 14.8% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 52.0% |
| Accounts Receivable | Nkr21.88 Million | 6.1% |
| Inventory | Nkr16.16 Million | 4.5% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Arcticzymes Technologies ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Arcticzymes Technologies ASA.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arcticzymes Technologies ASA's current assets represent 85.2% of total assets in 2025, an increase from 60.1% in 2002.
- Cash Position: Cash and equivalents constituted 52.0% of total assets in 2025, up from 33.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 6.1% of total assets.
Arcticzymes Technologies ASA Competitors by Total Assets
Key competitors of Arcticzymes Technologies ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Arcticzymes Technologies ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.39 | 17.12 | 16.70 |
| Quick Ratio | 15.53 | 16.17 | 16.35 |
| Cash Ratio | 0.00 | 10.26 | 0.00 |
| Working Capital | Nkr289.06 Million | Nkr268.57 Million | Nkr182.64 Million |
Arcticzymes Technologies ASA - Advanced Valuation Insights
This section examines the relationship between Arcticzymes Technologies ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.33 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | Nkr361.41 Million |
| Market Capitalization | $117.69 Million USD |
Valuation Analysis
Below Book Valuation: The market values Arcticzymes Technologies ASA's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Arcticzymes Technologies ASA's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Arcticzymes Technologies ASA (2002–2025)
The table below shows the annual total assets of Arcticzymes Technologies ASA from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr361.41 Million ≈ $38.03 Million |
+4.98% |
| 2024-12-31 | Nkr344.26 Million ≈ $36.23 Million |
+1.46% |
| 2023-12-31 | Nkr339.32 Million ≈ $35.71 Million |
+6.36% |
| 2022-12-31 | Nkr319.04 Million ≈ $33.57 Million |
+12.29% |
| 2021-12-31 | Nkr284.11 Million ≈ $29.90 Million |
+28.03% |
| 2020-12-31 | Nkr221.91 Million ≈ $23.35 Million |
+185.93% |
| 2019-12-31 | Nkr77.61 Million ≈ $8.17 Million |
+14.11% |
| 2018-12-31 | Nkr68.02 Million ≈ $7.16 Million |
+10.27% |
| 2017-12-31 | Nkr61.68 Million ≈ $6.49 Million |
-28.13% |
| 2016-12-31 | Nkr85.83 Million ≈ $9.03 Million |
-15.08% |
| 2015-12-31 | Nkr101.07 Million ≈ $10.64 Million |
-9.05% |
| 2014-12-31 | Nkr111.13 Million ≈ $11.69 Million |
+106.64% |
| 2013-12-31 | Nkr53.78 Million ≈ $5.66 Million |
+66.83% |
| 2012-12-31 | Nkr32.24 Million ≈ $3.39 Million |
-42.89% |
| 2011-12-31 | Nkr56.44 Million ≈ $5.94 Million |
-18.17% |
| 2010-12-31 | Nkr68.98 Million ≈ $7.26 Million |
-25.19% |
| 2009-12-31 | Nkr92.20 Million ≈ $9.70 Million |
-50.90% |
| 2008-12-31 | Nkr187.77 Million ≈ $19.76 Million |
-14.47% |
| 2007-12-31 | Nkr219.54 Million ≈ $23.10 Million |
+77.41% |
| 2006-12-31 | Nkr123.75 Million ≈ $13.02 Million |
-11.98% |
| 2005-12-31 | Nkr140.59 Million ≈ $14.79 Million |
+140.00% |
| 2004-12-31 | Nkr58.58 Million ≈ $6.16 Million |
-10.55% |
| 2003-12-31 | Nkr65.49 Million ≈ $6.89 Million |
+757.74% |
| 2002-12-31 | Nkr7.63 Million ≈ $803.39K |
-- |
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal… Read more